JonesTrading raises target for Praxis Precision Medicines stock
JonesTrading has increased its price target for Praxis Precision Medicines (PRAX) stock from USD 441.00 to USD 534.00, maintaining a Buy rating. This adjustment reflects the company's progress with its late-stage central nervous system pipeline. Despite a Q2 2026 GAAP net loss of USD 83.72 million, the analyst's target is significantly above the current Nasdaq price, signaling confidence in the company's development-focused financial profile and clinical progress.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. announced that its Compensation Committee granted restricted stock unit awards covering 3,478 shares to fourteen new non-executive employees on October 1, 2026. These grants were made under the 2024 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4), to attract new talent. The awards vest in four equal annual installments, contingent on continued employment.
Fourteen new employees receive Praxis stock awards covering 3,478 shares.
Praxis Precision Medicines (PRAX) announced it granted restricted stock units covering 3,478 common shares to fourteen new non-executive employees on October 1, 2026. These awards, issued under the 2024 Inducement Plan, are an inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4). The units will vest in four equal annual installments, contingent upon continued employment.
JonesTrading Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $534
JonesTrading has reiterated its Buy rating for Praxis Precision Medicines (PRAX.US) and increased the target price to $534. This update reflects the firm's continued confidence in the company's prospects.
FDA Extends Relutrigine Review, Delays PDUFA to December
The FDA has extended its review of Praxis Precision Medicines' New Drug Application (NDA) for relutrigine, an investigational therapy for SCN2A- and SCN8A-related developmental and epileptic encephalopathy (DEE), by three months, pushing the PDUFA date to December 27, 2026. This extension was due to additional sensitivity analyses submitted by Praxis, not new safety or manufacturing concerns. The company is confident in its data package and is progressing with launch preparations for the therapy, which holds breakthrough, orphan, and rare pediatric disease designations.
(PRAX) as a Liquidity Pulse for Institutional Tactics
This article analyzes Praxis Precision Medicines Inc. (PRAX) using AI models to provide insights into institutional trading strategies. It highlights weak near-term and mid-term sentiment but a strong long-term outlook, offering specific strategies for position trading, momentum breakout, and risk hedging with entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal strengths and support/resistance levels.
Remagine Labs Pty Ltd announced that it has received funding from Praxis Precision Medicines, Inc., Monash Investment Holdings, Innovation Victoria Pty Ltd
Remagine Labs Pty Ltd has successfully closed a funding round led by new investor Praxis Precision Medicines, Inc. The round also saw participation from existing investors Monash Investment Holdings and Innovation Victoria Pty Ltd. The company issued convertible preferred stock as part of this transaction.
Sixty-six new employees receive stock awards from Praxis. They vest over four years.
Praxis Precision Medicines (PRAX) has granted inducement restricted stock unit awards covering 11,535 shares of common stock to 66 new non-executive employees on September 1, 2026. These awards were issued under the company’s 2024 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units will vest in four equal annual installments, contingent on the employees' continued employment.
S&P 500 Futures Drop in Premarket Trading; Praxis Precision Meds, Science Applications Lead
S&P 500 futures saw a decline in premarket trading. Despite this, Praxis Precision Medicines Inc. (PRAX) and Science Applications International Corp. (SAIC) were notable gainers, rising by 15.7% and 8.1% respectively, ahead of the U.S. stock market opening.
Breakeven On The Horizon For Praxis Precision Medicines, Inc. (NASDAQ:PRAX)
This article analyzes Praxis Precision Medicines, Inc. (NASDAQ:PRAX) and discusses its path to profitability. It focuses on the company's financial performance, analyst expectations regarding its breakeven point, and the potential for future growth.
Goldman Sachs Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $575
Goldman Sachs has reiterated its Buy rating for Praxis Precision Medicines (PRAX.US) and increased its target price for the company to $575. This indicates a positive outlook from the investment bank regarding the company's future performance.
Praxis Precision Medicine Number of Employees 2026 | Employee Count & Headcount Data
Praxis Precision Medicines, Inc. (PRAX) had 208 employees worldwide as of March 2026, representing a 120.6% growth from 94 employees in 2023. The company, headquartered in Boston, Massachusetts, is actively hiring with 81 job postings in 2026, a 117.6% increase from the previous year. While overall employee sentiment is negative, it shows improvement, and the average salary is $162,227, though it experienced a 3.3% year-over-year decrease in 2026.
Oppenheimer Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $650
Oppenheimer has reiterated its Buy rating for Praxis Precision Medicines (PRAX.US) and maintained its target price at $650. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Praxis Precision Medicines stock hits 52-week high at 388.27 USD
Praxis Precision Medicines Inc. (PRAX) stock has reached a new 52-week high of $388.27, representing a 721.64% increase over the past year. Despite the impressive growth and investor confidence, InvestingPro data suggests the stock may be overvalued and highly volatile. The company recently reported a narrower-than-expected loss for Q2 2026 and received an increased price target from Raymond James, citing confidence in its EMERALD trial and future drug launches.
Praxis Precision Medicines stock hits 52-week high at 388.27 USD
Praxis Precision Medicines (PRAX) stock has reached a new 52-week high of $388.27, marking a 721.64% increase over the past year with a market capitalization of $10.77 billion. Despite being unprofitable, this surge reflects investor confidence and recent positive developments, including a narrower-than-expected Q2 2026 loss and a raised price target from Raymond James. However, InvestingPro data suggests the stock might be overvalued with high volatility.
Praxis Precision Medicines stock hits 52-week high at 388.27 USD
Praxis Precision Medicines Inc. (PRAX) stock has reached a new 52-week high of $388.27, representing a 721.64% increase over the past year. Despite this impressive growth, the company remains unprofitable with an EPS of -$12.86, and InvestingPro data suggests the stock may be overvalued. Raymond James recently raised its price target for PRAX to $945, maintaining a "Strong Buy" rating, citing increased confidence in the company's EMERALD trial and upcoming neurology drugs.
Raymond James raises Praxis Precision Medicines price target on pipeline outlook
Raymond James has increased its price target for Praxis Precision Medicines Inc. (NASDAQ:PRAX) shares from $765 to $945, maintaining a Strong Buy rating. This upgrade is driven by an increased probability of success for the company's EMERALD trial and higher peak sales forecasts for relutrigine, with the firm anticipating significant catalysts in the next 6-12 months including the EMERALD readout, ulixacaltamide's PDUFA date, and its essential tremor launch. Despite the stock's impressive 679% gain over the past year, InvestingPro suggests it may be overvalued.
9,840 Shares in Praxis Precision Medicines, Inc. $PRAX Purchased by Handelsbanken Fonder AB
Handelsbanken Fonder AB recently acquired 9,840 shares of Praxis Precision Medicines (NASDAQ:PRAX) valued at approximately $3.29 million, contributing to institutional investors owning 67.84% of the company. Praxis Precision Medicines reported a smaller-than-expected quarterly loss of $2.87 per share and holds a consensus "Buy" rating from analysts with an average price target of $573.05. Despite director Jill Desimone selling a significant number of shares, the company's stock opened at $366.81, near its 52-week high.
Praxis Precision Medicines (PRAX): Orbis, Allan Gray disclose 5.5% ownership stake
Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have jointly disclosed a 5.5% ownership stake in Praxis Precision Medicines (PRAX), amounting to 1,529,788 shares of common stock as of June 30, 2026. Orbis holds the majority with 1,526,680 shares, while Allan Gray Australia holds 3,108 shares, with both firms exercising sole voting and dispositive power over their respective holdings. This disclosure was made via an amended Schedule 13G/A filing, indicating that they are non-U.S. institutions equivalent to investment advisers.
(PRAX) and the Role of Price-Sensitive Allocations
This article provides a detailed AI-driven analysis of Praxis Precision Medicines Inc. (NASDAQ: PRAX), highlighting a strong overweight bias across all time horizons. It outlines specific institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report also notes an exceptional risk-reward short setup for PRAX.
Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 12-Month High - Here's Why
Praxis Precision Medicines (NASDAQ:PRAX) recently hit a new 52-week high of $382.97, driven by positive analyst sentiment, including maintained "Buy" ratings and high price targets from HC Wainwright and RBC. The company beat quarterly EPS expectations and is anticipated to have significant catalysts in H2 2026 with potential regulatory decisions and late-stage clinical readouts. Despite near-term cash burn concerns, analysts project a transition from development-stage losses to substantial earnings in the long term.
Equities Analysts Offer Predictions for PRAX Q3 Earnings
HC Wainwright has revised its Q3 2026 EPS estimate for Praxis Precision Medicines (NASDAQ:PRAX) to a loss of $3.86 per share, maintaining a "Buy" rating and a $1,201 price target, indicating expectations for profitability by Q4 2027. Several other analysts also weighed in on the stock, with a consensus "Buy" rating and an average target price of $573.05. The company recently reported a Q3 loss of $2.87 per share, beating consensus estimates, and institutional investors hold a significant portion of its shares.
H.C. Wainwright Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,201
H.C. Wainwright has reiterated its Buy rating for Praxis Precision Medicines (PRAX.US), maintaining a target price of $1,201. This indicates continued confidence from the firm in the company's future performance.
Dimensional Fund Advisors LP Has $10.04 Million Holdings in Praxis Precision Medicines, Inc. $PRAX
Dimensional Fund Advisors LP significantly increased its stake in Praxis Precision Medicines (NASDAQ:PRAX) by 32.4% in the first quarter, bringing its total holdings to $10.04 million. Institutional investors and hedge funds now collectively own 67.84% of the company, while insiders own 3%. Despite a director's sale of shares, PRAX reported an earnings beat and maintains a "Buy" rating with an average analyst price target of $573.05, though the stock is trading near its 52-week high.
Praxis Precision Medicines, Inc. (PRAX) stock price, news, quote and history
This page provides a comprehensive overview of Praxis Precision Medicines, Inc. (PRAX) stock, including its current price, historical data, key statistics, and company profile. It details the company's focus on developing therapies for CNS disorders and lists its pipeline of clinical-stage and preclinical drug candidates. The article also presents performance metrics, earnings trends, analyst insights, and financial highlights for PRAX.
Praxis Precision Medicines (PRAX) Wins FDA Breakthrough Tag As CNS Pipeline Advances
Praxis Precision Medicines (PRAX) has achieved a significant milestone with its investigational treatment Elsunersen receiving FDA Breakthrough Therapy designation, advancing its central nervous system pipeline. Despite this regulatory success and other late-stage assets, the company reported substantial net losses and no meaningful revenue in Q2 2026, highlighting that its story remains focused on future potential. Investors should monitor regulatory progress on lead assets and quarterly financial updates to assess the company's balance between R&D investment and potential dilution.
Praxis Precision Medicines (PRAX) Wins FDA Breakthrough Tag As CNS Pipeline Advances
Praxis Precision Medicines announced significant clinical and regulatory advancements in its central nervous system (CNS) pipeline, including the FDA Breakthrough Therapy designation for Elsunersen. Despite these pipeline successes and expanded collaborations, the company continues to operate with no meaningful revenue and substantial losses, highlighting its reliance on future potential over current cash generation. Investors are advised to monitor regulatory progress on lead assets like relutrigine and ulixacaltamide, as well as financial updates on net loss and share count to assess the sustainability of its strategy.
Praxis Precision Medicines, Inc. Stock 12‑Month Price Target Raised to $620.95, Implies 95% Upside
Praxis Precision Medicines, Inc. (PRAX) has seen its average 12-month stock price target raised to $620.95 by 19 analysts, up from $604.83. This new target suggests a potential upside of approximately 95% from its recent closing price. The consensus analyst rating for PRAX remains a "Buy," with 17 out of 19 analysts recommending a buy.
Glenmede Trust Co. NA Sells 2,878 Shares of Praxis Precision Medicines, Inc. $PRAX
Glenmede Trust Co. NA significantly reduced its stake in Praxis Precision Medicines, Inc. (PRAX) by selling 2,878 shares, retaining 3,410 shares valued at approximately $1.1 million. Despite this, other institutional investors like Swiss National Bank and Geode Capital Management LLC increased their positions. Analysts maintain a "Moderate Buy" rating with a consensus price target of $563.85, even as some have lowered their individual targets.
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Praxis Precision Medicines announced significant progress in Q2 2026, with ulixacaltamide and relutrigine advancing towards FDA approval, including positive mid-cycle meetings and no major safety concerns identified. The company also received a third Breakthrough Therapy Designation for elsunersen, strengthening its CNS portfolio. Praxis reported cash and investments of $1.4 billion, extending its financial runway into 2028, and is accelerating commercial infrastructure build-out for anticipated product launches.
Praxis Precision Medicines (NASDAQ: PRAX) holds $1.4B cash, advances NDAs
Praxis Precision Medicines reported a Q2 2026 net loss of $83.7 million and a first-half loss of $176.3 million, driven by increased R&D and G&A expenses to fund clinical programs and commercial preparation. Despite these losses, the company holds $1.4 billion in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2028. Praxis is advancing its pipeline with NDAs for ulixacaltamide and relutrigine under FDA review, and elsunersen having received breakthrough therapy designation, although one vormatrigine study missed its primary endpoint.
Praxis Precision Medicines stock hits 52-week high at 366.7 USD
Praxis Precision Medicines Inc. (PRAX) has reached a new 52-week high of $366.70, reflecting a 557% one-year return and a market cap of $9.92 billion, despite an InvestingPro analysis suggesting it may be overvalued. The company recently reported a Q2 2026 loss of $2.87 per share, beating analyst expectations, and had positive mid-cycle FDA meetings for two key drugs, ulixacaltamide HCl and relutrigine, with PDUFA dates set for 2027 and 2026 respectively.
Praxis Precision Medicines beats Q2 loss estimates; shares rise
Praxis Precision Medicines Inc. (NASDAQ:PRAX) reported a Q2 loss of $2.87 per share, outperforming analyst estimates. The company's shares rose 6.5% in premarket trading following the news, which also highlighted progress with FDA interactions for its drug candidates ulixacaltamide HCl and relutrigine, and a third Breakthrough Therapy Designation for elsunersen. Praxis reported $1.4 billion in cash and investments, expected to fund operations into 2028.
Praxis Precision Medicines stock hits 52-week high at 366.7 USD
Praxis Precision Medicines Inc. (PRAX) has reached a new 52-week high of $366.70, with shares currently trading at $369.68, reflecting a 557% one-year return. The company's stock is experiencing high volatility, indicated by a beta of 2.78, and despite potential overvaluation, analysts maintain a strong buy consensus. Recent developments include exceeding Q2 loss expectations and positive FDA feedback on ulixacaltamide HCl and relutrigine, with PDUFA dates set for early 2027 and late 2026, respectively.
Q2 2026 Praxis Precision Medicines Inc Earnings Call Transcript
Praxis Precision Medicines Inc. held its Q2 2026 earnings call, discussing positive FDA feedback for ulixacaltamide and relutrigine, and strong financial positioning with $1.4 billion in cash. The company also addressed the setback in its vormatrigine program and reported increased operating expenses and cash burn due to launch preparations. Key points include successful BIMO inspections and a new Breakthrough Therapy Designation for elsunersen, alongside extended PDUFA dates and potential tolerability issues for some products.
Praxis Precision earnings on deck as commercialization nears
Praxis Precision Medicines Inc. is set to report second-quarter results, with investors focused on cash burn and commercial readiness as the company awaits two key FDA drug approval decisions. Analysts have a strong buy rating with significant upside potential. The company's cash runway and progress on clinical trials for relutrigine and ulixacaltamide are critical ahead of upcoming regulatory milestones.
Praxis Precision earnings on deck as commercialization nears By Investing.com
Praxis Precision Medicines Inc. is set to report second-quarter earnings, with investors focused on cash burn and commercialization efforts ahead of two key FDA approval decisions for relutrigine and ulixacaltamide. Analysts anticipate a wider loss for the quarter but maintain a "strong buy" rating with significant upside potential. The company's ability to manage costs and execute its commercial launch strategy will be critical as it approaches potential market entries in late 2026 and early 2027.
29 New Praxis Employees Get Stock Units, Four-Year Vesting
Praxis Precision Medicines (PRAX) announced the grant of restricted stock unit (RSU) awards covering 7,318 common shares to 29 new non-executive employees. These inducement grants, made under the 2024 Inducement Plan and Nasdaq Listing Rule 5635(c)(4), will vest in four equal annual installments, contingent on continued employment. This move aims to attract and retain talent, aligning employee incentives with the company's long-term success.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. announced that its Compensation Committee granted restricted stock unit awards covering 7,318 shares to 29 new non-executive employees on August 3, 2026. These grants were made under the company's 2024 Inducement Plan as material inducements for employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards will vest in four equal annual installments, contingent on continued employment.
Responsive Playbooks and the PRAX Inflection
This article analyzes Praxis Precision Medicines Inc. (NASDAQ: PRAX), highlighting weak near and mid-term sentiment that contrasts with a positive long-term outlook. The report identifies no clear price positioning signals and notes elevated downside risk. It also provides three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, including support and resistance levels.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. announced that its Compensation Committee granted restricted stock unit awards covering 7,318 shares of common stock to twenty-nine new non-executive employees. These grants were made under the 2024 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4), to attract new talent. The awards will vest in four equal annual installments, contingent on continued employment.
Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Praxis Precision Medicines, Inc. announced it will report its financial results for the second quarter ended June 30, 2026, and provide a corporate update on Thursday, August 6, 2026, before market open. The company will host a conference call and live webcast at 8:30 am ET to discuss these results and updates. A replay of the webcast will be available on their website for approximately 90 days.
Praxis Precision Medicines Inc (PRAX) Financial Health: Profitability & Balance Sheet Analysis
This article analyzes the financial health of Praxis Precision Medicines Inc (PRAX), which currently holds a financial score of 6.42, ranking 245 out of 384 in the Biotechnology & Medical Research industry. The company's financial status is stable with low operating efficiency. Key financial metrics such as cash and cash equivalents, total assets, total liabilities, and free cash flow have not yet been disclosed by the company, impacting the assessment of its quality of earnings, operational efficiency, growth potential, and shareholder returns.
Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) announced it will report its Q2 2026 financial results and provide a corporate update on Thursday, August 6, 2026, before market open. The company will also host a conference call and live webcast at 8:30 am ET on the same day to discuss the results and update. This event will be accessible via their investor relations website.
Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Praxis Precision Medicines, Inc. announced it will release its second-quarter financial results for the period ended June 30, 2026, and provide a corporate update on Thursday, August 6, 2026, before market open. The company will host a conference call and live webcast at 8:30 am ET on the same day to discuss the results and update. A replay of the webcast will be available on their website for approximately 90 days.
Praxis will webcast its second-quarter update Aug. 6 at 8:30 a.m.
Praxis Precision Medicines (NASDAQ: PRAX) announced it will report its Q2 2026 financial results and provide a corporate update on Thursday, August 6, 2026, before markets open. The company will host a conference call and live webcast at 8:30 a.m. ET on the same day to discuss developments and review the quarter. Investors can access the webcast via the company's website, with a replay available for approximately 90 days.
Praxis Precision Medicines Inc (PRAX) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Praxis Precision Medicines Inc (PRAX), noting its current risk score of 2.04, which ranks it 242 out of 384 in the Biotechnology & Medical Research industry. The company's beta value of 2.75 indicates higher volatility compared to the S&P 500. The assessment also details various financial risk metrics, including maximum drawdown, volatility, and liquidity.
PRAX Reiterated by BTIG -- Price Target Maintained at $810
BTIG analyst Kambiz Yazdi reiterated a "Buy" rating for Praxis Precision Medicine (PRAX) and maintained an $810 price target despite the stock showing significant overvaluation at a 1114.8% premium to its GF Value™. The stock's GF Score™ of 38/100 highlights concerns in profitability and growth, alongside negative insider activity, urging caution for investors.
PRAX|Praxis Precision Medicines Inc|Price:293.038|Chg%:-2.772
This article provides a comprehensive stock analysis of Praxis Precision Medicines Inc (PRAX), highlighting its relatively healthy fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. Despite a recent weak stock market performance, the company shows strong fundamentals and high institutional ownership, with analysts rating it as a "Buy" with significant upside potential. Praxis is a clinical-stage biopharmaceutical company focused on central nervous system disorders, developing therapies through its Cerebrum and Solidus platforms.
Praxis Precision Medicines Inc (PRAX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides an overview of Praxis Precision Medicines Inc.'s (PRAX) shareholder structure, detailing major shareholders, institutional holdings, and related ETF investments. Key shareholders include Janus Henderson Investors and Perceptive Advisors LLC, with significant institutional ownership changes over recent quarters. The data covers shareholder types, institutional holding trends, and specific shareholder activity.
